**Table S1** Patients characteristic of 24 NPC patients

| Patient name | Patient ID | Gender | Age at diagnosis (yrs) | Induction chemotherapy regimen | Radiotherapy regime | Pathological TNM | Clinical stage | TNB | TMB | TPS | CPS | EB virus (copies/mL) | Response |
|--------------|------------|--------|------------------------|--------------------------------|---------------------|-----------------|---------------|-----|-----|-----|-----|-------------------|----------|
| ads          | P1         | Female | 46                     | DOC + NDP + 5FU                | IMRT                | T4N1            | IVA           | 23  | 24.14 | 2%  | 10% | <500              | PR       |
| ccs          | P2         | Male   | 54                     | DOC + NDP + 5FU                | IMRT                | T4N2            | IVA           | 15  | 22.47 | 30% | 50% | 4250              | CR       |
| ch           | P3         | Female | 49                     | DOC + NDP + 5FU                | IMRT                | T4N1            | IVA           | 46  | 1.57  | 10% | 10% | 500               | PR       |
| cxl          | P4         | Male   | 46                     | DOC + NDP + 5FU                | IMRT                | T4N2            | IVA           | 20  | 22.76 | 5%  | 10% | 1600              | PR       |
| hjh          | P5         | Male   | 52                     | DOC + DDP + CAP               | IMRT                | T4N1            | IVA           | 15  | 17.24 | 2%  | 7%  | -                 | -        |
| jxl          | P6         | Male   | 45                     | DOC + NDP + 5FU                | IMRT                | T2N3            | IVA           | 19  | 21.38 | 5%  | 5%  | 1850              | -        |
| lj           | P7         | Male   | 41                     | DOC + NDP + 5FU                | IMRT                | T3N1            | III           | 6   | 7.59  | -    | -    | 1350              | PR       |
| lch          | P8         | Male   | 54                     | DOC + NDP                    | IMRT                | T4N2            | IVA           | 2   | 2.75  | 1%  | 30% | 1000              | NA       |
| myl          | P9         | Male   | 52                     | DOC + NDP + 5FU                | IMRT                | T3N1            | III           | 89  | 2.84  | 5%  | 5%  | -                 | PR       |
| qgx          | P10        | Female | 45                     | DOC + NDP + 5FU                | IMRT                | T3N2            | III           | 55  | 1.97  | 5%  | 20% | 1150              | -        |
| sj           | P11        | Female | 30                     | DOC + NDP                    | IMRT                | T3N0            | III           | /   | /     | 5%  | 20% | 55%               | PR       |
| wyl          | P12        | Female | 41                     | DOC + NDP                    | IMRT                | T4N1            | IVA           | /   | /     | 1%  | 20% | -                 | CR       |
| wb           | P13        | Male   | 40                     | DOC + DDP + CAP               | IMRT                | T4N2            | IVA           | 7   | 13.11 | 5%  | 2%  | 3450              | PR       |
| wkx          | P14        | Male   | 43                     | DOC + NDP                    | IMRT                | T3N3            | IVA           | 60  | 3.37  | -    | -    | /                 | /        |
| wl           | P15        | Male   | 51                     | DOC + NDP + 5FU                | IMRT                | T3N3            | IVA           | /   | /     | 2%  | 1%  | -                 | CR       |
| xwx          | P16        | Female | 44                     | DOC + NDP + 5FU                | IMRT                | T4N2            | IVA           | /   | /     | 50% | 1%  | 2050              | -        |
| xhf          | P17        | Male   | 58                     | DOC + DDP + 5FU                | IMRT                | T4N2            | IVA           | /   | /     | 15% | 30% | <500              | PR       |
| yzc          | P18        | Male   | 47                     | DOC + NDP + CAP               | IMRT                | T3N3            | IVA           | /   | /     | 2%  | 3%  | <500              | -        |
| yls          | P19        | Male   | 56                     | GEM + DDP                    | IMRT                | T4N2            | IVA           | 27  | 35.14 | -    | 2%  | <500              | SD       |
| zc           | P20        | Male   | 48                     | DOC + NDP + 5FU                | IMRT                | T3N2            | III           | /   | /     | 10% | 2%  | 850               | SD       |
| zsq          | P21        | Male   | 47                     | DOC + NDP                    | IMRT                | T1N1            | II            | /   | /     | 80% | 50% | 2050              | CR       |
| zjx          | P22        | Male   | 19                     | DOC + NDP + 5FU                | IMRT                | T4N2            | IVA           | /   | /     | 95% | 40% | -                 | CR       |
| zm           | P23        | Male   | 64                     | GEM + DDP                    | IMRT                | T3N2            | III           | 43  | 41.64 | 1%  | -    | -                 | SD       |
| cyq          | P24        | Male   | 55                     | DOC + NDP + 5FU                | IMRT                | T3N3            | III           | 3   | 2.07  | 5%  | 5%  | 1500              | CR       |

NPC, nasopharyngeal carcinoma; DOC, Docetaxel; NDP, Nedaplatin; 5FU, fluorouracil; DDP, Cisplatin; CAP, Capsaicin; GEM, Gemcitabine; /, missing; --, negative; CR, complete response; PR, partial response; NR, no response; NA, not available.